Affymetrix slides on preliminary 3Q12 results

Microarray company Affymetrix Inc. (NASDAQ:AFFX) fell $0.60 (14%) to $3.71 on Monday after saying it expects 3Q12 revenue to be about $80 million, below the Street's estimate of $84.6 million. Affymetrix said its gene expression and eBioscience business segments were negatively affected by a "tightening" academic funding environment. Affymetrix will report full results on Oct. 31. ...